| Literature DB >> 31355524 |
Jialin Meng1,2,3, Yi Liu1,2,3, Shiyang Guan4, Song Fan1,2,3, Jun Zhou1,2,3, Meng Zhang1,2,3, Chaozhao Liang1,2,3.
Abstract
Prostate cancer (PCa), a severe health burden for males, accounts for the second frequent cancer and fifth tumor specific death cancer around the world. Several studies on tumor-infiltrating immune cells (TIICs) have shown inconsistent and controversial results to PCa. We downloaded a gene expression matrix and clinical information from TCGA, and CIBERSORT was used to identify the proportion of TIICs. Wilcoxon's Sign Rank Test evaluated different gene expression levels in PCa and normal tissues. Kaplan-Meier curves were used to evaluate the associations of TIICs and recurrence-free survival (RFS). Finally, based on the preset P-value of .05, the distribution of TIICs in 73 PCa tissues and 11 normal tissues was illustrated. Activated CD4+ T cells and M0 macrophages account for a high proportion in PCa tissues, while neutrophils and monocytes were found at a high density in normal tissues. Further results showed that the density of plasma cells, Treg cells and resting mast cells were associated with advanced PCa. Additionally, M2 macrophages affected the RFS of PCa patients, and AR was also involved. In the current study, we first evaluated the immune infiltration among PCa and revealed that M2 macrophages could predict the prognosis of PCa patients. Meanwhile, based on the LASSO regression analysis, we established a novel nomogram to assess the recurrence risk of PCa based on immune cell proportions and clinical features.Entities:
Keywords: macrophages; nomogram; prognosis; prostate cancer; recurrence-free survival; tumor-infiltrating immune cells
Mesh:
Substances:
Year: 2019 PMID: 31355524 PMCID: PMC6718526 DOI: 10.1002/cam4.2433
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1Flowchart detailing the study design and samples at each stage of analysis. CIBERSORT, cell type identification by estimating relative subsets of known RNA transcripts; TGCA, The Cancer Genome Atlas
Figure 2The performance of cell type identification by estimating relative subsets of known RNA transcripts for characterizing tumor‐infiltrating immune cells (TIIC), composition in prostate cancer (PCa), and control tissues. A, The difference of immune infiltration in each sample of PCa and control tissues. B, The quantified contrast of the distribution of TIIC subtypes between PCa and control tissues
Figure 3The landscape of immune infiltration in prostate cancer. A and B, Correlation matrix of all 21 immune cell densities in the TCGA cohort. C, Heat map of the 21 immune cell proportions. The horizontal axis displays the grouping data of samples divided into two major categories
Clinical characteristics of prostate cancer patients from TCGA database
| Recurrence (n = 11) | No recurrence (n = 62) | Total | |
|---|---|---|---|
| Age (years) | 61.73 ± 5.20 | 61.37 ± 6.95 | 61.42 ± 6.68 |
| Gleason score, n (%) | |||
| 6 + 7+8 | 6 (8.22) | 38 (52.05) | 44 (60.27) |
| 9 + 10 | 5 (6.85) | 24 (32.88) | 29 (39.73) |
| Pathology T stage | |||
| T2 | 0 | 19 (26.03) | 18 (24.66) |
| T3 + T4 | 11 (15.07) | 43 (58.90) | 54 (73.97) |
| Pathology N stage | |||
| N0 | 6 (8.22) | 38 (52.05) | 44 (60.27) |
| N1 | 5 (6.85) | 16 (21.92) | 21 (28.77) |
| Histological type, n (%) | |||
| Adenocarcinoma Acinar | 11 (15.07) | 60 (82.19) | 71 (97.26) |
| Others | 0 | 2 (2.74) | 2 (2.74) |
T stage of 1 patient was not available.
N stage of 8 patients was not available.
Figure 4Immune infiltration in different clinical stages and recurrence‐free survival (RFS). Macrophage distribution in different Gleason scores (A) and pathology T stage (B); K‐M curves show the different RFS in the high‐ and low‐density of three types of macrophage. P‐values are from log‐rank tests. [Correction added on 5 August 2019, after first online publication: In Figure 4C, the legend (Red and Blue line) that represent “High risk” and “Low risk” was interchanged. This has been corrected in this version.]
Figure 5Established prostate cancer (PCa) recurrence prediction nomogram. A, Developed nomogram to predict the recurrence risk of PCa patients based on clinical parameters and proportions of tumor‐infiltrating immune cells. B, ROC curve performed to assess the performance of the PCa recurrence predictive nomogram. C, Decision curve analysis for the PCa recurrence predictive nomogram
Figure 6AR and M2 macrophage markers. TIMER was conducted to assess the co‐expression of AR and M2 macrophage markers, such as CD163 (A), MRC1 (B), VSIG4 (C), CCL24 (D), NS4A4A (E), and CD209 (F)